The Novartis deal will quietly die
The FDA's position on requiring an RCT for acute graft vs host will be confirmed
The multiple class action suits against the company will proceed.
I have concerns about how the LBP trial is going to turn out.
2021 Not going to be a good year for MSB unfortunately.
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-329
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.48 |
Change
0.105(7.64%) |
Mkt cap ! $1.689B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.49 | $1.38 | $8.181M | 5.685M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25443 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 60811 | 4 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |